Indications for FIBRICOR:

Adjunct to diet in severe hypertriglyceridemia (≥500mg/dL), and to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia. Limitations of use: was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes.

Adult Dosage:

Hypertriglyceridemia: 35–105mg/day, adjust at 4–8 week intervals. Hypercholesterolemia, dyslipidemia: 105mg/day. Renal impairment: initially 35mg/day. Discontinue if inadequate response after 2 months on max dose.

Children Dosage:

Not established.

FIBRICOR Contraindications:

Severe renal dysfunction (including dialysis). Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver function abnormalities. Gallbladder disease. Nursing mothers.

FIBRICOR Warnings/Precautions:

Renal impairment: monitor. Monitor CBCs for first year; monitor liver function; discontinue if ALT levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, gallstones, hypersensitivity reactions, or paradoxical decreases in HDL occur. Elderly. Pregnancy (Cat.C).

FIBRICOR Classification:


FIBRICOR Interactions:

May potentiate oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with colchicine, immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.

Adverse Reactions:

Abnormal liver tests, increased AST, increased ALT, increased CPK, rhinitis; myopathy, pancreatitis, cholelithiasis, hematological changes, hypersensitivity reactions (may be severe).

How Supplied:

Tabs 35mg—30, 105mg—30, 90

Pricing for FIBRICOR

105mg tablet (Qty: 90)
Appx. price $241